C. Mallinckrodt

发表

Comparison of Several Multiple Imputation Strategies for Repeated Measures Analysis of Clinical Scales: To Truncate or Not To?

I. Lipkovich, Z. Kadziola, Lei Xu, 2014, Journal of biopharmaceutical statistics.

Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses.

J. Krystal, R. Gueorguieva, C. Mallinckrodt, 2011, Archives of general psychiatry.

A Latent‐Class Mixture Model for Incomplete Longitudinal Gaussian Data

G. Molenberghs, G. Verbeke, C. Beunckens, 2008, Biometrics.

Mechanical strain, induced noninvasively in the high-frequency domain, is anabolic to cancellous bone, but not cortical bone.

C. Rubin, K. McLeod, C. Mallinckrodt, 2002, Bone.

Attrition in Randomized Controlled Clinical Trials: Methodological Issues in Psychopharmacology

A. Leon, C. Chuang-Stein, C. Mallinckrodt, 2006, Biological Psychiatry.

Anabolism: Low mechanical signals strengthen long bones

C. Rubin, K. McLeod, C. Mallinckrodt, 2001, Nature.

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

Craig Mallinckrodt, Anantha Shekhar, Christian C Felder, 2008, The American journal of psychiatry.

Analyzing Incomplete Discrete Longitudinal Clinical Trial Data

Geert Molenberghs, Geert Verbeke, Craig Mallinckrodt, 2006, math/0606497.

Adjusting for Baseline on the Analysis of Repeated Binary Responses With Missing Data

G. Molenberghs, I. Lipkovich, P. Kulkarni, 2015 .

An evaluation of the trimmed mean approach in clinical trials with dropout

G. Molenberghs, C. Mallinckrodt, ming-Dauh Wang, 2018, Pharmaceutical statistics.

Type I error rates from likelihood‐based repeated measures analyses of incomplete longitudinal data

R. Carroll, G. Molenberghs, M. Detke, 2004 .

A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence.

R. Dean, K. Schuh, R. Anton, 2014, Alcoholism, clinical and experimental research.

The impact of analytic method on interpretation of outcomes in longitudinal clinical trials

C. Mallinckrodt, R. Risser, A. Prakash, 2008, International journal of clinical practice.

Efficacy and safety of continuous every‐2‐week dosing of ixekizumab over 52 weeks in patients with moderate‐to‐severe plaque psoriasis in a randomized phase III trial (IXORA‐P)

M. Gooderham, K. Papp, P. Foley, 2018, The British journal of dermatology.

The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder*

D. Sheehan, J. Russell, C. Mallinckrodt, 2008 .

Using principal stratification in analysis of clinical trials

B. Ratitch, I. Lipkovich, Y. Qu, 2021, 2112.03352.

A case study comparing a randomized withdrawal trial and a double‐blind long‐term trial for assessing the long‐term efficacy of an antidepressant

M. Detke, C. Chuang-Stein, L. Alphs, 2007, Pharmaceutical statistics.

Placebo Response and Antidepressant Clinical Trial Outcome

M. Detke, C. Mallinckrodt, Arif Khan, 2003, The Journal of nervous and mental disease.

Utility of positive controls in assessing assay sensitivity in ICH S7B and ICH E14 guidance for evaluation of QT/QTc interval prolongation.

A. Dmitrienko, C. Mallinckrodt, A. Chiang, 2010, Journal of pharmacological and toxicological methods.

Mortality in beagles irradiated during prenatal and postnatal development. II. Contribution of benign and malignant neoplasia.

Arthur C. Lee, T. Keefe, C. Mallinckrodt, 1998, Radiation research.

Non-neoplastic and neoplastic thyroid disease in beagles irradiated during prenatal and postnatal development.

C. Mallinckrodt, G. M. Angleton, A. C. Lee, 1997, Radiation research.

Considerations for Comparing a Test Drug with Standard of Care in Phase 2 Clinical Trials of Central Nervous System Disorders

G. Molenberghs, M. Detke, S. Ruberg, 2010 .

Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.

D. Stewart, S. Kornstein, C. Mallinckrodt, 2006, Journal of affective disorders.

Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine.

M. Fava, P. Delgado, J. Greist, 2005, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.

M. Detke, S. Brannan, G. Tollefson, 2005, Journal of psychiatric research.

An Open-label Study of Duloxetine for the Treatment of Major Depressive Disorder: Comparison of Switching Versus Initiating Treatment Approaches

M. Fava, C. Mallinckrodt, J. Martinez, 2005, Journal of clinical psychopharmacology.

Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study

C. Mallinckrodt, J. Watkin, M. Wohlreich, 2004, BMC geriatrics.

The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials

M. Detke, C. Mallinckrodt, J. Raskin, 2004, BMC psychiatry.

Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.

J. Greist, C. Mallinckrodt, J. Raskin, 2004, Clinical therapeutics.

Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines.

G. Molenberghs, B. Ratitch, N. Goel, 2019, Therapeutic innovation & regulatory science.

Evaluation of Cisplatin in Combination with a Biologic Response Modifier in a Murine Mammary Carcinoma Model

M. Manning, C. A. Kuntz, E. Morello, 2002, Cancer investigation.

ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELS

C H Mallinckrodt, W. S. Clark, C. Mallinckrodt, 2001, Journal of biopharmaceutical statistics.

Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine

M. Detke, M. Demitrack, C. Mallinckrodt, 2002, European Neuropsychopharmacology.

Phase III Trials

C. Mallinckrodt, V. Whitmyer, 2014 .

Using principal stratification in analysis of clinical trials

B. Ratitch, I. Lipkovich, Y. Qu, 2021, Statistics in medicine.

Dose-response effects of estradiol implants on bone mineral density in ovariectomized ewes.

C. Mallinckrodt, H. Bryant, A. Turner, 1995, Bone.

Dual-energy X-ray absorptiometry in sheep: experiences with in vivo and ex vivo studies.

C. Mallinckrodt, H. Bryant, A. Turner, 1995, Bone.

The effect of selective reporting on estimates of weaning weight parameters in beef cattle.

C. Mallinckrodt, R. Bourdon, B. Golden, 1995, Journal of animal science.

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

M. Demitrack, C. Mallinckrodt, Yili Lu, 2002, The Journal of clinical psychiatry.

Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.

D. Stewart, S. Kornstein, C. Mallinckrodt, 2006, The Journal of clinical psychiatry.

Assessing Response Profiles from Incomplete Longitudinal Clinical Trial Data Under Regulatory Considerations

Geert Molenberghs, Raymond J. Carroll, Craig H. Mallinckrodt, 2003, Journal of biopharmaceutical statistics.

Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years.

D. Stewart, M. Detke, V. Burt, 2005, Psychosomatics.

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.

A. Schatzberg, S. Brannan, C. Mallinckrodt, 2005, Journal of psychiatric research.

Choosing estimands in clinical trials with missing data

G. Molenberghs, C. Mallinckrodt, S. Rathmann, 2017, Pharmaceutical statistics.

The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials.

M. Detke, J. Nelson, C. Mallinckrodt, 2006, Primary care companion to the Journal of clinical psychiatry.

Surgery and doxorubicin in dogs with hemangiosarcoma.

G. Ogilvie, B. Powers, C. Mallinckrodt, 1996, Journal of veterinary internal medicine.

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

M. Detke, C. Mallinckrodt, Fujun Wang, 2006, European Psychiatry.

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.

C. Mallinckrodt, J. Watkin, A. Andorn, 2006, Journal of psychiatric research.

Analyzing incomplete longitudinal clinical trial data.

Geert Molenberghs, Michael G Kenward, Raymond J Carroll, 2004, Biostatistics.

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

S. Haeberlein, I. Nestorov, A. Sandrock, 2020, Alzheimer's & Dementia.

Approximate confidence intervals for heritability from method R estimates.

A. Reverter, C. Mallinckrodt, B. Golden, 1997, Journal of animal science.

Relationship of maternal milk expected progeny differences to actual milk yield and calf weaning weight.

C. Mallinckrodt, R. Bourdon, R. Schalles, 1993, Journal of animal science.

Mortality in beagles irradiated during prenatal and postnatal development. I. Contribution of non-neoplastic diseases.

T. Keefe, C. Mallinckrodt, G. M. Angleton, 1998, Radiation research.

ORIGINAL RESEARCH—PSYCHOLOGY: Changes in Sexual Functioning Associated with Duloxetine, Escitalopram, and Placebo in the Treatment of Patients with Major Depressive Disorder

S. Kornstein, C. Mallinckrodt, A. Clayton, 2007 .

Associations between Lymphocytic Thyroiditis, Hypothyroidism, and Thyroid Neoplasia in Beagles

C. Mallinckrodt, G. M. Angleton, A. C. Lee, 1996, Veterinary pathology.

Radiofrequency (electrosurgical) ablation of articular cartilage: a study in sheep.

C H Mallinckrodt, B. Powers, C. Mallinckrodt, 1998, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association.

Intraarticular lidocaine and bupivacaine in sheep undergoing stifle arthrotomy.

C. Mallinckrodt, A. Turner, P. Hellyer, 2001, Veterinary anaesthesia and analgesia.

Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice

G. Molenberghs, B. Ratitch, I. Lipkovich, 2020, Therapeutic Innovation & Regulatory Science.

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice

G. Molenberghs, B. Ratitch, N. Goel, 2020, Therapeutic Innovation & Regulatory Science.

Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).

G. Ogilvie, C. Mallinckrodt, K. Valerius, 1997, Journal of the American Veterinary Medical Association.

Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.

S. Kornstein, C. Mallinckrodt, A. Clayton, 2007, The journal of sexual medicine.

Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab

A. Blauvelt, P. C. van de Kerkhof, K. See, 2018, The Journal of dermatological treatment.

Points to consider for analyzing efficacy outcomes in long‐term extension clinical trials

Bohdana Ratitch, Ilya Lipkovich, Janelle Shannon Erickson, 2018, Pharmaceutical statistics.

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo‐controlled clinical trials

D. Kajdasz, C. Mallinckrodt, J. Hudson, 2005, Human psychopharmacology.

Assessing and interpreting treatment effects in longitudinal clinical trials with missing data

Geert Molenberghs, Craig H Mallinckrodt, Raymond J Carroll, 2003, Biological Psychiatry.

Platelet function in dogs treated for lymphoma and hemangiosarcoma and supplemented with dietary n-3 fatty acids.

G. Ogilvie, M. J. Fettman, C. Mallinckrodt, 1999, Journal of veterinary internal medicine.

Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features

C. Mallinckrodt, Chaofeng Liu, J. Raskin, 2005, BMC psychiatry.

Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis.

C. Mallinckrodt, J. Raskin, M. Sullivan, 2009, Psychosomatics.

Covariate Adjustment for Logistic Regression Analysis of Binary Clinical Trial Data

G. Molenberghs, I. Lipkovich, P. Kulkarni, 2017 .

To adjust or not to adjust for baseline when analyzing repeated binary responses? The case of complete data when treatment comparison at study end is of interest

G. Molenberghs, I. Lipkovich, P. Kulkarni, 2015, Pharmaceutical statistics.

Effect of fish oil, arginine, and doxorubicin chemotherapy on remission and survival time for dogs with lymphoma

G. Ogilvie, M. J. Fettman, M. Hand, 2000, Cancer.

The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?

Craig H Mallinckrodt, Maurizio Fava, M. Fava, 2004, The Journal of clinical psychiatry.

The impact of missing data and how it is handled on the rate of false‐positive results in drug development

Craig H Mallinckrodt, Stacy R Lindborg, Sunni A Barnes, 2008, Pharmaceutical statistics.

Analyzing Longitudinal Clinical Trial Data: A Practical Guide

I. Lipkovich, C. Mallinckrodt, 2016 .

Choice of the primary analysis in longitudinal clinical trials

Geert Molenberghs, Raymond J. Carroll, Craig H. Mallinckrodt, 2004 .

Methods of Dealing with Missing Data

Craig Mallinckrodt, C. Mallinckrodt, 2013 .

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

Craig Mallinckrodt, M. Demitrack, C. Mallinckrodt, 2002, The Journal of clinical psychiatry.

Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology

M. Detke, W. Potter, C. Mallinckrodt, 2014, Pharmaceutical Medicine.

Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials.

Craig H Mallinckrodt, Yoko Tanaka, R. Tamura, 2011, Journal of psychiatric research.

Signal detection and placebo response in schizophrenia: parallels with depression.

C. Mallinckrodt, W. R. Prucka, B. Millen, 2010, Psychopharmacology bulletin.

Simple options for improving signal detection in antidepressant clinical trials.

M. Detke, C. Mallinckrodt, D. Faries, 2007, Psychopharmacology bulletin.

Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology

M. Detke, W. Potter, C. Mallinckrodt, 2014, Pharmaceutical Medicine.

Preventing and Treating Missing Data in Longitudinal Clinical Trials: A Practical Guide

Craig Mallinckrodt, C. Mallinckrodt, 2013 .

Does pain mediate the pain interference with sleep problem in chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine.

D. Fishbain, C. Mallinckrodt, A. Meyers, 2008, Journal of pain and symptom management.

Statistics issues relevant to CNS drug development

G. Molenberghs, C. Mallinckrodt, W. R. Prucka, 2012 .

Considerations for Using Positive Controls in Phase 2 Clinical Trials of Central Nervous System Disorders

G. Molenberghs, M. Detke, S. Ruberg, 2010 .

Design Archetypes for Phase 2 Clinical Trials in Central Nervous System Disorders

G. Molenberghs, M. Detke, S. Ruberg, 2010 .

Determination of Vitamin E Status and Supplementation for Nyala (Tragelaphus angasi)

Phillips, M., T. Grandin, 2002 .

Using daily interactive voice response assessments: to measure onset of symptom improvement with duloxetine.

M. Fava, J. Mundt, J. Greist, 2007, Psychiatry (Edgmont (Pa. : Township)).

Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.

M. Detke, P. Delgado, S. Brannan, 2005, The Journal of clinical psychiatry.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

M. Detke, I. Bitter, M. Demitrack, 2004, European Neuropsychopharmacology.

Duloxetine for the treatment of major depressive disorder in older patients.

M. Detke, J. Nelson, C. Mallinckrodt, 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Causal Inference and Estimands in Clinical Trials

Bohdana Ratitch, Ilya Lipkovich, Craig H. Mallinckrodt, 2020 .

Estimands, Estimators and Sensitivity Analysis in Clinical Trials

Geert Molenberghs, Bohdana Ratitch, Ilya Lipkovich, 2019 .

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice.

G. Molenberghs, B. Ratitch, N. Goel, 2019, Therapeutic innovation & regulatory science.

Duloxetine in treatment of anxiety symptoms associated with depression

Craig Mallinckrodt, M. Detke, D. Dunner, 2003, Depression and anxiety.

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder*

L. Arnold, C. Mallinckrodt, T. Pigott, 2007, Current medical research and opinion.

Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice.

A. Gottlieb, R. Burge, K. See, 2018, The Journal of investigative dermatology.

A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.

D. Dunner, S. Kornstein, J. Greist, 2007, The Journal of clinical psychiatry.

Cardiovascular Profile of Duloxetine, a Dual Reuptake Inhibitor of Serotonin and Norepinephrine

M. Thase, M. Detke, C. Mallinckrodt, 2005, Journal of clinical psychopharmacology.

Duloxetine in the long-term treatment of major depressive disorder.

C. Mallinckrodt, D. Goldstein, J. Raskin, 2003, The Journal of clinical psychiatry.

Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression

R. Shelton, M. Detke, C. Mallinckrodt, 2007, International clinical psychopharmacology.

Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression.

M. Detke, C. Mallinckrodt, Yili Lu, 2003, Primary care companion to the Journal of clinical psychiatry.

The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA

Geert Molenberghs, Craig H Mallinckrodt, Raymond J Carroll, 2004, Clinical trials.

The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials.

D. Kajdasz, C. Mallinckrodt, T. Wise, 2008, Primary care companion to the Journal of clinical psychiatry.

Why Missing Data Matter

C. Mallinckrodt, 2013 .

Patterns of depressive symptom response in duloxetine‐treated outpatients with mild, moderate or more severe depression

R. Shelton, M. Detke, C. Mallinckrodt, 2007, International journal of clinical practice.

A Multiple-Imputation-Based Approach to Sensitivity Analyses and Effectiveness Assessments in Longitudinal Clinical Trials

Geert Molenberghs, Craig H Mallinckrodt, Ilya Lipkovich, 2014, Journal of biopharmaceutical statistics.

Differential Antidepressant Symptom Efficacy: Placebo-Controlled Comparisons of Duloxetine and SSRIs (Fluoxetine, Paroxetine, Escitalopram)

M. Fava, M. Detke, C. Mallinckrodt, 2007, Neuropsychobiology.

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study*

A. Nierenberg, J. Greist, G. Tollefson, 2007, Current medical research and opinion.

The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder.

D. Sheehan, J. Russell, C. Mallinckrodt, 2008, Current medical research and opinion.

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation

C. Mallinckrodt, J. Watkin, W. P. Carter, 2007, Depression and anxiety.

Type I Error Rates from Mixed Effects Model Repeated Measures Versus Fixed Effects Anova with Missing Values Imputed Via Last Observation Carried Forward

Craig H. Mallinckrodt, W. S. Clark, C. Mallinckrodt, 2001 .

Time course of depression‐symptom improvement during treatment with duloxetine

M. Detke, R. Hirschfeld, C. Mallinckrodt, 2005, Depression and anxiety.

Conceptual Considerations regarding Endpoints, Hypotheses, and Analyses for Incomplete Longitudinal Clinical Trial Data

Michael G. Kenward, Craig H. Mallinckrodt, M. Kenward, 2009 .

Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials

Yahong Peng, C. Mallinckrodt, P. Lane, 2008 .

Bone Mineral Density of the Skull in Premenopausal Women

C. Mallinckrodt, A. Turner, J. Maillet, 1997, Calcified Tissue International.

Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines

G. Molenberghs, B. Ratitch, N. Goel, 2020, Therapeutic Innovation & Regulatory Science.

Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses.

M. Fava, D. Dunner, C. Mallinckrodt, 2005, Current therapeutic research, clinical and experimental.

Central and peripheral temperature changes in sheep following ovariectomy.

C. Mallinckrodt, H. Bryant, E. Lehmer, 2003, Maturitas.

The effect of raloxifene on coronary arteries in aged ovariectomized ewes.

C. Mallinckrodt, H. Bryant, A. Turner, 2000, Journal of veterinary pharmacology and therapeutics.

Using longitudinal data from a clinical trial in depression to assess the reliability of its outcome scales.

G. Molenberghs, A. Alonso, A. Laenen, 2009, Journal of psychiatric research.

The Enrichment Window Approach as a Means of Dealing with Placebo Response in Antidepressant Clinical Trials

C. Mallinckrodt, W. R. Prucka, 2010, Clinical pharmacology and therapeutics.

A structured approach to choosing estimands and estimators in longitudinal clinical trials

C H Mallinckrodt, I Lipkovich, G Molenberghs, 2012, Pharmaceutical statistics.

Response profiles for longitudinal clinical trial data with subject dropout under regulatory considerations

R. Carroll, G. Molenberghs, W. S. Clark, 2003 .

Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice.

G. Molenberghs, B. Ratitch, I. Lipkovich, 2019, Therapeutic innovation & regulatory science.

Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients.

C. Blanco, C. Mallinckrodt, J. Watkin, 2006, The Journal of clinical psychiatry.

Duloxetine for the treatment of major depressive disorder.

M. Detke, C. Nemeroff, A. Schatzberg, 2002, Psychopharmacology bulletin.

Comparing onset of antidepressant action using a repeated measures approach and a traditional assessment schedule

R. Carroll, G. Molenberghs, M. Detke, 2006, Statistics in medicine.

Does pain mediate the pain interference with sleep problem in chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine.

D. Fishbain, C. Mallinckrodt, A. Meyers, 2008, Journal of pain and symptom management.

The challenges of evaluating dose response in flexible‐dose trials using marginal structural models

I. Lipkovich, C. Mallinckrodt, D. Faries, 2012, Pharmaceutical statistics.

Causal Inference and Estimands

Geert Molenberghs, Bohdana Ratitch, Ilya Lipkovich, 2019 .

Evaluating dose response from flexible dose clinical trials

I. Lipkovich, D. Baron, C. Mallinckrodt, 2008, BMC psychiatry.

Nonparametric covariate adjustment in estimating hazard ratios

Yanping Wang, P. Kulkarni, Honghua H. Jiang, 2016, Pharmaceutical statistics.

Recent Developments in the Prevention and Treatment of Missing Data

B Ratitch, M O'Kelly, G Molenberghs, 2014, Therapeutic innovation & regulatory science.

Missing Data: Turning Guidance Into Action

Geert Molenberghs, Bohdana Ratitch, Russell D. Wolfinger, 2013 .

A Multiple-Imputation-Based Approach to Sensitivity Analyses and Effectiveness Assessments in Longitudinal Clinical Trials

G. Molenberghs, I. Lipkovich, C. Mallinckrodt, 2014, Journal of biopharmaceutical statistics.

A bootstrap approach to confidence regions for genetic parameters from Method R estimates.

C H Mallinckrodt, A Reverter, A. Reverter, 1998, Journal of Animal Science.

Coping With Memory Effect and Serial Correlation When Estimating Reliability in a Longitudinal Framework

G. Molenberghs, A. Laenen, C. Mallinckrodt, 2010 .

A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy.

M. Detke, D. Dunner, S. Kornstein, 2008, The Journal of clinical psychiatry.